Anti-CDKN2A (Isoform 1)/P16INK4A antibody produced in goat

Cyclin dependent kinase inhibitor 2A (CDKN2A), also known as P16-INK4A, arrests cell cycle progression by inhibiting S-phase and promotes apoptosis. The encoded protein has anti-proliferative biological activity, and is implicated in the retinoblastoma (Rb) protein pathway. P16-INK4A acts as a tumor suppressor and plays a vital role in ageing and cellular senescence. Increased expression of this protein might lead to various types of high grade cancers. P16-INK4A also facilitates cell invasion and angiogenesis. Bronchial lavage P16INK4A promoter methylation might function as a potential biomarker for diagnosis of lung cancer.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

Cyclin dependent kinase inhibitor 2A (CDKN2A), also known as P16-INK4A, belongs to the Ink4 (inhibitor of CDK4) family of CDK inhibitors. It is encoded by the gene mapped to human chromosome 9p21 within the INK4a/ alternate reading frame (ARF) locus. Human P16-INK4A is localized in both nucleus and cytoplasm, and its expression increases with ageing in skin and kidney tissues.

Peptide with sequence C-HARIDAAEGPSDIPD from the C Terminus of the protein sequence according to NP_000068.1.

Supplied at 0.5 mg/mL in Tris saline with 0.02% sodium azide and 0.5% bovine serum albumin.